Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
08/29/2014
Trade Name:
Taclonex
Generic Name or Proper Name (*):
calcipotriene/ betamethasone dipropionate
Indications Studied:
Plaque psoriasis of the scalp
Label Changes Summary:
Expanded the indication from adults to pediatric patients 12 – 17 years Safety and effectiveness have not been established in pediatric patients less than 12 years In a trial to evaluate the effect on HPA axis suppression in pediatric patients 12 – 17 years, adrenal suppression was identified in 1 of 30 patients (3.3%) after 4 weeks of treatment Rare systemic toxicities such as Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids Local adverse reactions including striae have also been reported with use of topical corticosteroids in pediatric patients Information on dose and maximum weekly dose, adverse reactions, and clinical trials Postmarketing study
Product Labeling:
Labeling
PREA(P):
P
Sponsor:
LEO Pharma
NNPS:
FALSE'
Therapeutic Category:
Anti-inflammatory, topical
-
-